Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Protective Activity of Monoclonal Antibodies to Genome-Derived Neisserial Antigen 1870, a Neisseria meningitidis Candidate Vaccine

1 May 2004

Abstract excerpt

Genome-derived neisserial Ag (GNA) 1870 is a meningococcal vaccine candidate that can be subdivided into three variants based on amino acid sequence variability. Variant group 1 accounts for approximately 60% of disease-producing group B isolates. The Ag went unrecognized until its discovery by genome mining because it is expressed in low copy number by most strains. To investigate the relationship between Ab...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bacterial Infections and Vaccines
Share to Neonatal and Maternal Infections
Share to Pneumonia and Respiratory Infections

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 15100304
DOI: 10.4049/jimmunol.172.9.5606

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Protective Activity of Monoclonal Antibodies to Genome-Derived Neisserial Antigen 1870, a Neisseria meningitidis Candidate VaccinePMID 15100304Read ↗

Protective Antibody Responses Elicited by a Meningococcal Outer Membrane Vesicle Vaccine with Overexpressed Genome‐Derived Neisserial Antigen 1870Semantic proximity Read ↗

Vaccination against <i>Neisseria meningitidis</i> Using Three Variants of the Lipoprotein GNA1870Semantic proximity Read ↗

Antibody to Genome‐Derived Neisserial Antigen 2132, a<i>Neisseria meningitidis</i>Candidate Vaccine, Confers Protection against Bacteremia in the Absence of Complement‐Mediated Bactericidal ActivitySemantic proximity Read ↗

Identification of Vaccine Candidates Against Serogroup B Meningococcus by Whole-Genome SequencingSemantic proximity Read ↗

The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance.Semantic proximity Read ↗

Rapid genetic grouping of factor h-binding protein (genome-derived neisserial antigen 1870), a promising group B meningococcal vaccine candidate.Semantic proximity Read ↗

The Development of a Vaccine Against Meningococcus B Using Reverse VaccinologySemantic proximity Read ↗

Meningococcal disease: changes in epidemiology and preventionSemantic proximity Read ↗

Towards the Immunoproteome of Neisseria meningitidisSemantic proximity Read ↗

Looking beyond meningococcal B with the 4CMenB vaccine: the Neisseria effectSemantic proximity Read ↗

How the Knowledge of Interactions between Meningococcus and the Human Immune System Has Been Used to Prepare Effective<i>Neisseria meningitidis</i>VaccinesSemantic proximity Read ↗

Cellular and molecular biology of <i>Neisseria meningitidis</i> colonization and invasive diseaseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.